Alteration to hippocampal shape in cannabis users with and without schizophrenia

Nadia Solowij; Mark Walterfang; Dan I Lubman; Sarah Whittle; Valentina Lorenzetti; Martin Styner; Dennis Velakoulis; Christos Pantelis; Murat Yuecel

Journal article

Alteration to hippocampal shape in cannabis users with and without schizophrenia

Nadia Solowij, Mark Walterfang, Dan I Lubman, Sarah Whittle, Valentina Lorenzetti, Martin Styner, Dennis Velakoulis, Christos Pantelis, Murat Yuecel

Schizophrenia Research | ELSEVIER SCIENCE BV | Published : 2013

DOI: 10.1016/j.schres.2012.10.040

University of Melbourne Researchers

Sarah Whittle Author Psychiatry

Mark Walterfang Author Psychiatry

Christos Pantelis Author Psychiatry

Dennis Velakoulis Author Psychiatry

Related Projects (4)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

RESEARCH FELLOWSHIP - PROF CHRISTOS PANTELIS

I have established and head the Melbourne Neuropsychiatry Centre within the University of Melbourne. My university position is a research ch..

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

Sensitivity to the environment: Risk and resilience for adolescent depression

Depression is among the leading causes of disability and disease burden throughout the world. Little is known about how biological and envir..

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia

Awarded by Australian Research Council

Awarded by NHMRC

Awarded by NIH

Funding Acknowledgements

This study was supported by grants from the Clive and Vera Ramaciotti Foundation for Biomedical Research, the National Health and Medical Research Council (NHMRC) of Australia (Project Grant 459111) and the Schizophrenia Research Institute using infrastructure funding from NSW Health. The study was also supported by the Australian Schizophrenia Research Bank (ASRB), which is supported by the NHMRC, the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. NS is supported by an Australian Research Council Future Fellowship (FT110100752). CP is supported by a NHMRC Senior Principal Research Fellowship 628386 and Program Grant 566529. MY is supported by a NHMRC Fellowship Award 1001973 and SW by a NHMRC Career Development Fellowship 1007716. MS is supported by NIH grants P40 HD 03110 (IDDRC) and U54 EB005149 (NA-MIC). No funding body had any further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.There are no conflicts of interests between the authors and the reported research. In the past three years, MW has provided consultancy for Actelion Pharmaceuticals Australia; DL has received speaking honoraria from Astra Zeneca Pharmaceuticals and Janssen-Cilag, as well as provided consultancy support to Lundbeck; DV has received speaking honoraria from Pfizer, Astra Zeneca, and Eli Lilly; CP has provided consultancy for Janssen-Cilag, Eli Lilly, Hospira (Mayne), Astra Zeneca, Pfizer, Schering Plough, and Lundbeck and has undertaken investigator initiated studies supported by Eli Lilly, Hospira, Janssen-Cilag, and Astra Zeneca; and MY has received a speaking honorarium from Janssen-Cilag. These activities are unrelated to the present work.